Rocket One Inc. (NASDAQ: RKTO) shares rose 8.5% on Monday after the company provided an update on its cash position and described its strategic direction in artificial intelligence and defense-related technologies.
In a regulatory filing, Rocket One reported cash and cash equivalents of approximately $8.4 million as of June 12, 2026. The company said this cash balance reflects proceeds from its previously disclosed at-the-market equity program.
Alongside the cash update, Rocket One outlined an emphasis on several technology areas: advanced computing technologies, artificial intelligence infrastructure, space systems, and defense-related technologies. As part of that focus, the company disclosed that it entered into two exclusive license agreements on May 15, 2026. The agreements relate to spintronic and nanomagnetic computing technologies intended for artificial intelligence and data-center applications.
The licensed intellectual property covers techniques described as all-spin matrix multiplication and nanomagnetic computing architectures. According to the company, these architectures are aimed at addressing power consumption, memory bottlenecks, and computational efficiency constraints found in modern artificial intelligence systems.
Rocket One also expanded its advisory resources. The company named Dr. Supriyo Bandyopadhyay as Lead Technical Advisor for AI Nanomagnetic Technology. In addition, Major General Malcolm B. Frost (Ret.) joined its Space and Defense Advisory Board, and Colonel Robert "Shane" Kimbrough (Ret.), a former NASA astronaut and International Space Station Commander, was added to the advisory lineup.
Despite the strategic tilt toward computing and defense technologies, Rocket One continues to own biotechnology assets carried over from its prior identity as Hoth Therapeutics. Those assets include HT-001, a clinical-stage program developed to address epidermal growth factor receptor inhibitor-associated skin toxicities. The company reported that the pharmacokinetic portion of the HT-001 Phase 2 clinical program has been completed and that it is awaiting finalized results.
Rocket One said it is evaluating strategic alternatives for its biotechnology portfolio. Potential paths under consideration include partnerships, licensing transactions, joint ventures, or asset sales. The company further stated an intention to assess strategic acquisitions, partnerships, and licensing opportunities that would complement its emphasis on advanced computing, AI infrastructure, space systems, and defense technologies.
Key points
- Cash position: Rocket One reported approximately $8.4 million in cash and cash equivalents as of June 12, 2026, reflecting proceeds from an at-the-market equity program.
- Technology focus: The company is prioritizing advanced computing, AI infrastructure, space systems, and defense-related technologies, and entered into exclusive licenses for spintronic and nanomagnetic computing on May 15, 2026.
- Advisory additions: New advisors include Dr. Supriyo Bandyopadhyay, Major General Malcolm B. Frost (Ret.), and Colonel Robert "Shane" Kimbrough (Ret.).
Risks and uncertainties
- Timing and outcome of HT-001 results: The pharmacokinetic portion of the HT-001 Phase 2 program is complete, but the company is awaiting finalized results, creating near-term uncertainty for that clinical asset - impacts the biotechnology sector.
- Strategic outcome uncertainty: Rocket One is evaluating a range of strategic alternatives for its biotech assets and considering acquisitions, partnerships, and licensing; there is no commitment to any specific transaction - impacts mergers and acquisitions activity in tech and biotech markets.
- Execution risk on technology licensing: The licensed nanomagnetic and spintronic technologies aim to address technical challenges in AI systems, but commercialization and integration outcomes are not guaranteed - impacts AI infrastructure and data-center sectors.
This update aligns Rocket One's disclosed resources and advisory hires with its stated strategic priorities while leaving several near-term outcomes - including finalized clinical results and decisions on biotechnology assets - unresolved.